Harpreet  Grewal net worth and biography

Harpreet Grewal Biography and Net Worth

Director of Penumbra
Harpreet Grewal has served on the Board since April 2015. Since September 2019, Mr. Grewal has served as Chief Operating Officer of Volante Technologies Inc., a global provider of software for the integration, processing and orchestration of payments and financial messages, where he also serves on the Board of Directors and served as Executive in Residence from April 2018 to March 2019. From February 2016 through April 2017, Mr. Grewal served as General Manager of Constant Contact, Inc. (Constant Contact), a technology company primarily focused on marketing tools and a wholly-owned indirect subsidiary of Endurance International Group Holdings, Inc. (Endurance). Prior to the acquisition of Constant Contact by Endurance, from 2010 to February 2016, Mr. Grewal served as Executive Vice President and Chief Financial Officer of Constant Contact. From 2008 to 2009, Mr. Grewal worked as an independent consultant to small businesses and early-stage entrepreneurs. From 2006 through 2008, Mr. Grewal was Executive Vice President and Chief Financial Officer of VistaPrint, Ltd., a publicly-traded online printing and marketing services company. Prior to VistaPrint, Mr. Grewal was Senior Vice President and Chief Financial Officer of GoldenSource Corporation, a data management company, from 2002 to 2006, Chief Financial Officer of eGain Communications Corporation, a customer engagement services company, from 1999 to 2002, and held various financial and strategic planning positions with PepsiCo, Inc., a publicly-traded food and beverage company, from 1996 to 1999. Mr. Grewal received a B.A. from the University of California, Berkeley and a M.A. from Johns Hopkins University.

What is Harpreet Grewal's net worth?

The estimated net worth of Harpreet Grewal is at least $2.12 million as of October 2nd, 2024. Mr. Grewal owns 8,697 shares of Penumbra stock worth more than $2,123,894 as of December 3rd. This net worth evaluation does not reflect any other investments that Mr. Grewal may own. Learn More about Harpreet Grewal's net worth.

How do I contact Harpreet Grewal?

The corporate mailing address for Mr. Grewal and other Penumbra executives is One Penumbra Place, Alameda CA, 94502. Penumbra can also be reached via phone at (510) 748-3200 and via email at [email protected]. Learn More on Harpreet Grewal's contact information.

Has Harpreet Grewal been buying or selling shares of Penumbra?

During the past quarter, Harpreet Grewal has sold $31,677.78 of Penumbra stock. Most recently, Harpreet Grewal sold 166 shares of the business's stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $190.83, for a transaction totalling $31,677.78. Following the completion of the sale, the director now directly owns 8,697 shares of the company's stock, valued at $1,659,648.51. Learn More on Harpreet Grewal's trading history.

Who are Penumbra's active insiders?

Penumbra's insider roster includes Arani Bose (Insider), Adam Elsesser (President, Chairman and CEO), Harpreet Grewal (Director), Don Kassing (Director), Bridget O'Rourke (Director), James Pray (Insider), Johanna Roberts (EVP), Surbhi Sarna (Director), and Thomas Wilder (Director). Learn More on Penumbra's active insiders.

Are insiders buying or selling shares of Penumbra?

In the last twelve months, insiders at the sold shares 22 times. They sold a total of 91,671 shares worth more than $19,415,521.66. The most recent insider tranaction occured on November, 20th when CEO Adam Elsesser sold 15,000 shares worth more than $3,559,200.00. Insiders at Penumbra own 5.0% of the company. Learn More about insider trades at Penumbra.

Information on this page was last updated on 11/20/2024.

Harpreet Grewal Insider Trading History at Penumbra

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/2/2024Sell166$190.83$31,677.788,697View SEC Filing Icon  
9/4/2024Sell782$204.11$159,614.028,863View SEC Filing Icon  
10/2/2023Sell170$240.99$40,968.309,150View SEC Filing Icon  
9/1/2023Sell340$266.62$90,650.809,320View SEC Filing Icon  
3/29/2023Sell875$271.00$237,125.009,660View SEC Filing Icon  
3/15/2023Sell875$254.98$223,107.5010,535View SEC Filing Icon  
3/1/2023Sell710$259.48$184,230.8011,410View SEC Filing Icon  
10/1/2021Sell634$267.06$169,316.04View SEC Filing Icon  
8/31/2021Sell732$271.21$198,525.72View SEC Filing Icon  
11/16/2020Sell567$262.77$148,990.59View SEC Filing Icon  
10/1/2019Sell237$134.93$31,978.41View SEC Filing Icon  
9/3/2019Sell475$144.81$68,784.75View SEC Filing Icon  
1/3/2019Sell666$121.27$80,765.8213,247View SEC Filing Icon  
10/2/2018Sell665$148.58$98,805.70View SEC Filing Icon  
8/27/2018Sell1,528$129.33$197,616.24View SEC Filing Icon  
10/5/2017Sell500$92.90$46,450.00View SEC Filing Icon  
8/21/2017Sell4,500$82.65$371,925.00View SEC Filing Icon  
See Full Table

Harpreet Grewal Buying and Selling Activity at Penumbra

This chart shows Harpreet Grewal's buying and selling at Penumbra by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Penumbra Company Overview

Penumbra logo
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Read More

Today's Range

Now: $245.87
Low: $242.70
High: $246.70

50 Day Range

MA: $217.76
Low: $186.89
High: $248.96

2 Week Range

Now: $245.87
Low: $148.00
High: $277.34

Volume

45,729 shs

Average Volume

377,314 shs

Market Capitalization

$9.44 billion

P/E Ratio

285.90

Dividend Yield

N/A

Beta

0.51